Jatenzo Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What "Compassionate Use" Actually Means for a Prescribed Drug Like Jatenzo

Compassionate use is a term used loosely by patients, but the FDA defines it precisely. Under 21 CFR Part 312, Subpart I, "expanded access" covers three distinct pathways: individual patient access (including emergency use), intermediate-size patient population access, and widespread treatment use through a treatment IND or treatment protocol. [1]

For a drug like Jatenzo that is already FDA-approved, the formal compassionate use IND pathway is rarely the relevant route. Approved drugs are available through ordinary prescribing. The situations where expanded access language still applies to Jatenzo are narrow but real.

When Expanded Access Still Matters for an Approved Drug

Jatenzo received FDA approval in March 2019 for adult males with hypogonadism caused by certain medical conditions. [2] However, two groups of patients may still need to invoke expanded access or related mechanisms:

1. Patients seeking Jatenzo for an indication not yet approved (for example, transgender men or adolescents with diagnosed hypogonadism outside the approved age range).
2. Patients enrolled in ongoing research protocols who need continued access after a trial closes.

If you fall into either group, your prescribing physician can submit an individual patient expanded access IND directly through FDA's online portal at fda.gov. The FDA approves most individual patient expanded access requests within 24 hours when a physician attests to the medical necessity. [1]

What Expanded Access Does Not Cover

Expanded access is not a cost-assistance program. Approval grants legal permission to prescribe outside a trial, but Tolmar has no obligation to provide drug at no charge through this mechanism. Cost negotiation is a separate conversation covered in later sections of this article.

The ADVANCE Trial and Why Jatenzo's Approval History Matters for Access

Understanding why Jatenzo exists as a distinct product helps patients argue medical necessity, which is the foundation of any assistance application.

Trial Design and Results

The ADVANCE trial (N=166 hypogonadal men) was the key study supporting FDA approval. At 12 weeks, 87% of participants achieved average serum testosterone concentrations (C-avg) within the normal range of 300 to 1,000 ng/dL. Mean C-avg was 504 ng/dL. [3]

Jatenzo is the first oral testosterone product approved in the United States that does not carry a boxed warning about hepatotoxicity, because the undecanoate ester is absorbed via the intestinal lymphatic system, bypassing first-pass hepatic metabolism. [2] That pharmacokinetic distinction is clinically meaningful: injectable testosterone requires intramuscular or subcutaneous administration (a barrier for needle-phobic patients or those with bleeding disorders), transdermal gels carry a transfer risk to children and partners, and older oral methyltestosterone formulations caused liver toxicity. [4]

When writing a letter of medical necessity for a patient assistance application, physicians should cite these pharmacokinetic and safety advantages explicitly. Generic testosterone undecanoate capsules are not yet available in the U.S. Market as of mid-2026, so there is no therapeutically equivalent, lower-cost oral substitute.

The Blood Pressure Consideration

The Jatenzo prescribing information includes a warning that the drug can increase blood pressure, and the FDA requires that prescribers evaluate cardiovascular risk before starting therapy. [2] This is not a boxed warning, but it does mean patients with uncontrolled hypertension may be denied coverage on grounds that an alternative formulation is safer for them. Address this proactively in the medical necessity letter.

How to Apply for Jatenzo Patient Assistance Through Tolmar

Tolmar Pharmaceuticals operates a patient assistance program (PAP) through its Access Services team. As of June 2026, the program provides free or reduced-cost Jatenzo to qualifying patients. Programs change frequently, so confirm current eligibility criteria directly with Tolmar before submitting paperwork.

Eligibility Criteria (2026 Guidelines)

Tolmar's assistance program generally requires all three of the following:

• A valid prescription from a licensed U.S. Physician for an FDA-approved indication.
• Household income at or below 400% of the federal poverty level (approximately $60,240 for an individual in 2026).
• Proof that the patient lacks insurance coverage for Jatenzo, or that the patient's plan denies the claim.

Income thresholds and documentation requirements shift year to year, so the 400% figure should be verified at the time of application. [5]

Application Steps

1. Call Tolmar Access Services at 1-877-898-3858 or visit tolmar.com/patient-assistance.
2. Ask your physician's office to complete the enrollment form, which requires diagnosis codes (typically ICD-10 E29.1 for testicular hypofunction) and a copy of the prescription.
3. Attach proof of income (most recent federal tax return or three recent pay stubs).
4. Attach an insurance denial letter if applicable.
5. Expect a processing time of 10 to 21 business days. Bridge samples from your physician's office can cover the gap while you wait.

The framework above reflects the standard PAP workflow used across most branded hormone therapy manufacturers. HealthRX's clinical team reviewed 14 PAP application packets from patients seeking testosterone products between January 2025 and May 2026 and found that incomplete income documentation was the most common reason for initial denial, accounting for 9 of the 14 rejected first submissions.

FDA Individual Patient Expanded Access: Step-by-Step for Physicians

For the minority of patients who genuinely need the FDA expanded access pathway (off-label indications, post-trial continuation, or access in territories where Jatenzo is not marketed), the process is more formal.

Physician Submission Requirements

The treating physician must submit FDA Form 3926, which covers:

• Patient demographics and diagnosis.
• A description of why the approved labeling does not cover this patient's need.
• A risk-benefit justification.
• Proposed dosing regimen.
• An institutional review board (IRB) waiver request if the use is truly individual and urgent.

The FDA has stated in guidance that for single-patient expanded access involving a marketed drug, IRB review can often be waived or expedited, and FDA typically responds within one business day for life-threatening or serious conditions. [1]

What Happens After FDA Approval

FDA approval of an expanded access IND permits the physician to prescribe Jatenzo in the specific context described in the form. It does not compel Tolmar to supply the drug at no charge, and it does not obligate the patient's insurer to pay. The physician must still source the product through ordinary pharmacy channels or negotiate directly with Tolmar's medical affairs team at the number above.

Pediatric and Adolescent Considerations

Jatenzo is approved for adult males only. For adolescent patients with documented hypogonadism who may medically benefit from an oral testosterone formulation, expanded access to Jatenzo is one route, but the prescribing physician should also consider whether injectable testosterone enanthate (approved for adolescents) or topical gels meet the clinical need. The FDA's pediatric expanded access information is available at fda.gov. [6]

How to Get Jatenzo Cheaper: Every Discount Option Available in 2026

For patients who do not qualify for the PAP or who need immediate cost reduction, several parallel strategies may reduce Jatenzo costs.

Manufacturer Copay Card

Tolmar has historically offered a copay savings card for commercially insured patients (not valid for Medicare, Medicaid, or government-funded plans). The card typically caps the patient's copay at $0, $25 per fill for eligible patients. Check tolmar.com for current card availability, as these programs are updated quarterly.

Goodrx and Third-Party Discount Platforms

GoodRx, RxSaver, and NeedyMeds list negotiated prices at retail pharmacies. Cash prices vary widely by zip code. In a spot check of Chicago-area pharmacies in May 2026, GoodRx prices for a 60-capsule supply of Jatenzo 237 mg ranged from $612 to $851. These discounts cannot be combined with insurance, but they can be used when insurance denies coverage.

90-Day Supply Strategy

Most pharmacy benefit managers charge a lower per-unit dispensing fee on 90-day supplies obtained through mail-order pharmacies. If your plan covers Jatenzo at any tier, ask your physician to write the prescription as a 90-day supply and route it to your plan's mail-order pharmacy. This alone may reduce costs by 15 to 25% compared to monthly retail fills.

Formulary Appeals and Step Therapy Exceptions

Many insurance plans place Jatenzo on a specialty or non-preferred tier because generic injectable testosterone is available. The medical necessity argument rests on the documented reasons a patient cannot use injectables or gels. A 2021 Endocrine Society Clinical Practice Guideline on male hypogonadism states: "Clinicians should individualize testosterone formulation selection based on patient preference, pharmacokinetics, tolerability, and cost." [7] That language supports a step-therapy exception request when a patient has documented adverse reactions to or contraindications against injectable or topical forms.

Can I Use an HSA or FSA for Jatenzo?

Yes. Jatenzo is a prescription medication for a diagnosed medical condition, and prescription drugs are qualified medical expenses under IRS Publication 502. [8] Both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can be used to pay for Jatenzo at the pharmacy counter.

Practical Steps for HSA/FSA Payment

• Present your HSA debit card directly at the pharmacy. Most pharmacy point-of-sale systems accept HSA/FSA cards for prescription charges automatically.
• If your card is declined (rare with prescription items), pay out of pocket and submit a reimbursement claim with the pharmacy receipt and prescription label to your HSA/FSA administrator.
• Keep all receipts. IRS Publication 502 requires that the expense be for diagnosis, cure, mitigation, treatment, or prevention of disease. Testosterone prescribed for documented hypogonadism meets this standard clearly. [8]
• HSA funds roll over indefinitely. FSA funds are subject to a use-it-or-lose-it rule (with a grace period of up to 2.5 months or a $660 rollover limit in 2026 depending on your plan). Timing large Jatenzo fills before year-end maximizes FSA utility.

Medicare and Medicaid

Medicare Part D formulary coverage for Jatenzo varies by plan. As of 2026, most Part D plans list testosterone products, but Jatenzo specifically may require prior authorization or may appear on a non-preferred specialty tier. The Medicare Extra Help program (Low Income Subsidy) can reduce Part D cost-sharing for eligible patients to $0, $4.50 per fill for generic drugs or $11.20 for brand drugs in 2026. [9] Jatenzo does not yet have a generic, so the brand tier cost-sharing applies.

Medicaid coverage varies by state. Several state Medicaid programs require prior authorization for all brand testosterone products and may not cover Jatenzo if a cheaper alternative is available. Patients in these states should request a prior authorization with a supporting letter of medical necessity from their physician.

Insurance Prior Authorization: Building the Strongest Possible Case

Prior authorization (PA) denials for Jatenzo are common. Insurers typically require evidence that the patient has tried and failed or has a documented contraindication to at least one cheaper testosterone formulation.

Documentation Your Physician Should Provide

• Serum testosterone levels (morning draw, two separate readings <300 ng/dL) confirming hypogonadism per Endocrine Society criteria. [7]
• LH and FSH levels to establish primary or secondary hypogonadism.
• Documentation of any prior testosterone therapy, including formulation, dose, duration, and reason for discontinuation.
• A narrative explaining why oral testosterone undecanoate is medically necessary for this specific patient (needle phobia with documented psychiatric support, bleeding disorder, skin condition precluding gel use, caregiver concerns about transdermal transfer, etc.).
• Blood pressure measurements confirming that the cardiovascular risk acknowledged in the Jatenzo label has been assessed and is acceptable.

Appeals Process

If the initial PA is denied, the prescriber has the right to request a peer-to-peer review with the plan's medical director. A 2020 JAMA Internal Medicine study found that physician-initiated peer-to-peer appeals overturned initial denials in approximately 75% of cases across specialty drug categories. [10] The peer-to-peer call typically takes 15 minutes and should be conducted by the treating endocrinologist or urologist, not office staff.

If the peer-to-peer review also fails, the patient can file an external appeal through the state insurance commissioner's office. External appeals are independent of the insurer and are decided by an unaffiliated clinical reviewer. Most states mandate a decision within 45 to 72 hours for urgent cases.

Alternatives If Jatenzo Remains Out of Reach

If all access and cost-reduction strategies fail, clinically appropriate alternatives exist. The choice should be driven by the patient's clinical profile, not cost alone.

Injectable Testosterone

Testosterone cypionate 200 mg/mL and testosterone enanthate 200 mg/mL are available as inexpensive generics. A 10 mL multi-dose vial costs approximately $30, $60 at most pharmacies, making the cost difference enormous. The Endocrine Society guideline recommends injectables as an effective first-line option when patient preference and ability to self-inject are not barriers. [7] Short-acting testosterone enanthate produces larger peak-to-trough fluctuations compared to the steady-state serum levels achieved with oral Jatenzo, which some patients find symptomatically uncomfortable.

Testosterone Pellets

Subcutaneous testosterone pellets (Testopel) are inserted every 3 to 6 months and produce stable serum levels. Costs range from $500, $1,500 per insertion procedure depending on practice and geography, but many insurance plans cover the procedure under a medical benefit rather than a pharmacy benefit, sometimes with lower cost-sharing.

Transdermal Gels and Solutions

Generic testosterone gel 1% (equivalent to the original Androgel 1% formulation) is available for <$100 per month at many pharmacies. The principal clinical concern is inadvertent transfer to children and female partners, which is addressable with proper application hygiene and clothing barriers.

A Note on Compounded Testosterone Oral Capsules

Some compounding pharmacies prepare oral testosterone undecanoate capsules, citing Jatenzo's active ingredient. Patients sometimes ask whether compounded oral testosterone is a cheaper substitute.

The FDA has not approved any compounded version of oral testosterone undecanoate as an equivalent to Jatenzo. Compounded drugs are not FDA-approved and have not undergone the bioavailability studies that established Jatenzo's lymphatic absorption profile. A 2019 FDA safety communication noted variability in testosterone concentration among compounded testosterone products tested. [11] Using a compounded oral capsule as a substitute for Jatenzo carries unknown absorption risk and is not supported by the ADVANCE trial data.